208
Views
16
CrossRef citations to date
0
Altmetric
Drug Evaluations

Zalutumumab in head and neck cancer

, MD, , FRCR, , FRCR, , PhD & , MD
Pages 119-125 | Published online: 15 Dec 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Assuntina G Sacco & Francis P Worden. (2016) Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. OncoTargets and Therapy 9, pages 1927-1943.
Read now
Nicholas P. Campbell, Thomas A. Hensing, Mihir K. Bhayani, Arif Y. Shaikh & Bruce E. Brockstein. (2016) Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Review of Anticancer Therapy 16:8, pages 847-858.
Read now
Gamze Ugurluer & Mahmut Ozsahin. (2014) Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer. Expert Opinion on Investigational Drugs 23:12, pages 1637-1654.
Read now

Articles from other publishers (13)

Amirhossein Tamimi, Atena Tamimi, Fatemeh Sorkheh, Saba Mardekatani Asl, Arezoo Ghafari, Arian Ghannadi Karimi, Gisou Erabi, Hossein Pourmontaseri & Niloofar Deravi. (2023) Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. Cancer Reports 6:5.
Crossref
Manisha Yadav, Sweety Mehra, Shivani Jassal, Sapna Kushwaha, Naresh Kumar, Subhash Chandra Sonkar & B.C. Koner. 2023. Treatment Landscape of Targeted Therapies in Oncology. Treatment Landscape of Targeted Therapies in Oncology 165 182 .
Yashika Jawa, Pooja Yadav, Shruti Gupta, Sivapar V. Mathan, Jyoti Pandey, Ajay K. Saxena, Suneel Kateriya, Ashu B. Tiku, Neelima Mondal, Jaydeep Bhattacharya, Shandar Ahmad, Rupesh Chaturvedi, Rakesh K. Tyagi, Vibha Tandon & Rana P. Singh. (2021) Current Insights and Advancements in Head and Neck Cancer: Emerging Biomarkers and Therapeutics with Cues from Single Cell and 3D Model Omics Profiling. Frontiers in Oncology 11.
Crossref
Seyed Ali Mosaddad, Kimia Beigi, Tayebeh Doroodizadeh, Maral Haghnegahdar, Farzaneh Golfeshan, Reza Ranjbar & Hamid Tebyanian. (2021) Therapeutic applications of herbal/synthetic/bio-drug in oral cancer: An update. European Journal of Pharmacology 890, pages 173657.
Crossref
Revathy Nadhan, Priya Srinivas & M. Radhakrishna Pillai. 2020. Receptor Tyrosine Kinases. Receptor Tyrosine Kinases 319 373 .
Arielle Elkrief, Nicholas Makhoul & Nathaniel Bouganim. 2020. Improving Outcomes in Oral Cancer. Improving Outcomes in Oral Cancer 117 128 .
Amaia Eleonora Maennling, Mehmet Kemal Tur, Marcus Niebert, Torsten Klockenbring, Felix Zeppernick, Stefan Gattenlöhner, Ivo Meinhold-Heerlein & Ahmad Fawzi Hussain. (2019) Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers 11:12, pages 1826.
Crossref
Miren Taberna, Marc Oliva & Ricard Mesía. (2019) Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology 9.
Crossref
S. Kareemaghay & M. Tavassoli. (2019) Clinical immunotherapeutic approaches for the treatment of head and neck cancer. International Journal of Oral and Maxillofacial Surgery 48:4, pages 419-436.
Crossref
Wiktoria Blaszczak, Wojciech Barczak, Anna Wegner, Wojciech Golusinski & Wiktoria Maria Suchorska. (2017) Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma. Medical Oncology 34:4.
Crossref
Matthew Zibelman & Ranee Mehra. (2016) Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology 39:4, pages 396-406.
Crossref
Chetan Yewale, Dipesh Baradia, Imran Vhora, Sushilkumar Patil & Ambikanandan Misra. (2013) Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials 34:34, pages 8690-8707.
Crossref
S. K. Kundu & M. Nestor. (2012) Targeted therapy in head and neck cancer. Tumor Biology 33:3, pages 707-721.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.